Lupin launches Ganirelix Acetate Injection

15 Feb 2024 Evaluate

Lupin has launched Ganirelix Acetate Injection, 250 mcg/0.5 mL, Single-Dose Prefilled Syringe, after having received an approval from the United States Food and Drug Administration (U.S. FDA).

Ganirelix Acetate Injection, 250 mcg/0.5 mL, Single-Dose Prefilled Syringe is a generic equivalent to the reference listed drug (RLD), Ganirelix Acetate Injection, 250 mcg/0.5 mL of Organon USA LLC. It is indicated for the inhibition of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation. Ganirelix Acetate Injection had estimated annual sales of $87 million in the U.S. (IQVIA MAT December 2023).

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally. 

Lupin Share Price

2159.65 12.10 (0.56%)
23-Dec-2024 14:07 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1817.55
Dr. Reddys Lab 1335.55
Cipla 1472.10
Lupin 2159.65
Zydus Lifesciences 971.05
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.